The British Medicines and Healthcare Products Regulatory Agency (MHRA) supports Merck's MET inhibitor Teppetko in the treatment of non-small cell lung cancer (NSCLC)

Recently, the British Medicines and Health Products Regulatory Agency (MHRA) has conditionally authorized Merck's MET inhibitor Teppetko (tepotinib) for the treatment of certain non-small cell lung cancer ( NSCLC ) patients
.

Non-small cell lung cancer is most common in older smokers and former smokers
.

Tepmetko's conditional marketing authorization provides treatment for adult patients with advanced NSCLC who carry a mesenchymal-epithelial transformation factor gene exon 14 (METex14) jumping mutation
.

MHRA's decision is based on the results of the Phase II VISION study, which evaluated the effectiveness of Teppetko monotherapy in patients with advanced or metastatic NSCLC with METex14 jumping mutations.
As of January 1, 2020, a total of 152 patients had received Teppetko.
For treatment, 99 patients were followed up for at least 9 months
.

Figure 1.
Overall Response Rate (ORR)

Lung Cancer Fund will be Roy Paula Chadwick Castle, CEO, said: "We welcome the decision to approve MHRA tepotinib targeted therapy
of lung cancer may be an aggressive, difficult to treat cancer, so we have to provide as many treatment options for patients.

Original source:

http:// href="http://" target="_blank" rel="noopener">http:// http:// Leave a message here